Published Date : Nov 07, 2013
The USFDA has approved an Indian pharmaceutical company Zydus Cadila to further perform Phase-1 clinical trials of ZYDPLA 1. In medical parlance, ZYDPLA 1 is a compound that blocks the enzyme Dipeptidyl Peptidase-4 (DPP-4) in order to treat type 2 diabetes. This novel compound called ZYDPLA 1 glucose helps to lower glucagon secretion in the body and increase the insulin secretion too. Hence, it results in a total improvement in the glucose homeostasis and a reduction in blood sugar levels.
This approval from USFDA for Zydus’ came around the launch time of NCE – Lipaglyn, the first drug to be approved for the cure of diabetes dislipidemia across the world.
The best part about the uniqueness of ZYDPLA 1 drug is that diabetic patients need to take this medicine as just one dose a week. At present, all the DPP-4 inhibitors are dosed once in every week.
Mr. Pankaj R Patel, Chairman and MD, Zydus Group said the IND approval from USFDA is good news for all of us. This new development has taken a major leap forward in the field of diabetes research. Now, the long-term management of type 2 diabetes can be treated better with ZYDPLA 1. Moreover, with the availability of ZYDPLA 1 drug one can now take up challenges to fight missions of reducing the burden of chronic diseases and also resolve issues that have not been addressed in order to meet medical needs in the treatment of diabetes.
According to global statistical data, there are over 360 million people suffering from diabetes throughout the world. It is calculated that by 2025, almost half of the diabetic population will be from countries such as China, India, Russia, Brazil, and Turkey. Further statistics have also stated that the sales of DPP-4 inhibitors are expected to rise to $14 billion by 2022.